Format

Send to

Choose Destination
BBA Clin. 2015 Nov 5;5:16-24. doi: 10.1016/j.bbacli.2015.11.002. eCollection 2016 Jun.

Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links.

Author information

1
Department of Anatomy Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, 1107-2020 Beirut, Lebanon; Lebanese Health Society, Beirut, Lebanon.
2
Department of Anatomy Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, 1107-2020 Beirut, Lebanon.
3
Lebanese Health Society, Beirut, Lebanon.
4
Oakland University William Beaumont School of Medicine, Rochester, MI, USA.
5
Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida MSD06, Malta.
6
Department of Experimental and Clinical Neurosciences, University of Palermo, 90133, Italy.
7
Department of Anatomy and Regenerative Biology, Georges Washington University, Washington, DC 20037, USA.

Abstract

The co-occurrence of the three disease entities, inflammatory bowel disease (IBD), colorectal cancer (CRC), type 2diabetes mellitus (T2DM) along with inflammation and dismicrobism has been frequently reported. Some authors have even suggested that dysbiosis could be the link through a molecular crosstalk of multiple inflammatory loops including TGFβ, NFKB, TNFα and ROS among others. This review focuses on the inflammatory process along with the role of microbiota in the pathophysiology of the three diseases. The etiology of IBD is multifactorial, and like CRC and T2DM, it is associated with a widespread and sustained GI inflammation and dismicrobism, whereby an array of pro-inflammatory mediators and other related biomolecules are up-regulated, both locally and systematically. Such a persistent or an inadequately resolved chronic inflammation may be a causative agent, in the presence other factors, leading to several pathologies such as IBD, CRC and T2DM. TGFβ plays a crucial role in pancreatic β cell malfunctioning as glucotoxicity stimulates its signaling cascade through smad 3, IL-6 and epithelial to mesenchymal transition. Such a cascade could lead to macrophages and other cells recruitment, inflammation, then IBD and CRC. NFkB is also another key regulator in the crosstalk among the pathways leading to the three disease entities. It plays a major role in linking inflammation to cancer development through its ability to up regulate several inflammatory and tumor promoting cytokines like: IL-6, IL-1 α and TNF α, as well as genes like BCL2 and BCLXL. It activates JAK/STAT signaling network via STAT3 transcription factors and promotes epithelial to mesenchymal transition. It also increases the risk for T2DM in obese people. In brief, NFKB is a matchmaker between inflammation, IBD, cancer and diabetes. In addition, TNFα plays a pivotal role in systemic inflammation. It is increased in the mucosa of IBD patients and has a central role in its pathogenesis. It also activates other signaling pathways like NFKB and MAPK leading to CRC. It is also overexpressed in the adipose tissues of obese patients thus linking it to T2DM, chronic inflammation and consequently CRC. On the other hand, increasing evidence suggests that dysbiosis plays a role in initiating, maintaining and determining the severity of IBD. Actually, among its functions, it modulates genotoxic metabolites which are able to induce CRC, a fact proven to be sustained by stool transfer from patients with CRC. Probiotics, however, may actively prevent CRC as well as IBD and results in a significant decrease in fasting glycemia in T2DM patients. In conclusion, IBD, CRC and T2DM are commonly occurring interrelated clinical problems. They share a common basis influenced by an inflammatory process, an imbalance in intestinal microbiota, and a crosstalk between various signaling pathways. Would probiotics interrupt the crosstalk or orient it in the physiological direction?

KEYWORDS:

CRC; Dysbiosis; IBD; Inflammation; Probiotic; T2DM

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center